BR112020020277A2 - Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto - Google Patents
Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto Download PDFInfo
- Publication number
- BR112020020277A2 BR112020020277A2 BR112020020277-0A BR112020020277A BR112020020277A2 BR 112020020277 A2 BR112020020277 A2 BR 112020020277A2 BR 112020020277 A BR112020020277 A BR 112020020277A BR 112020020277 A2 BR112020020277 A2 BR 112020020277A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- seq
- dose
- cfz533
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862657172P | 2018-04-13 | 2018-04-13 | |
| US62/657,172 | 2018-04-13 | ||
| EP18208332 | 2018-11-26 | ||
| EA18208332.9 | 2018-11-26 | ||
| PCT/IB2019/052976 WO2019198019A1 (en) | 2018-04-13 | 2019-04-11 | Anti-cd40 antibodies for use in prevention of graft rejection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020020277A2 true BR112020020277A2 (pt) | 2021-01-19 |
Family
ID=66542473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020020277-0A BR112020020277A2 (pt) | 2018-04-13 | 2019-04-11 | Anticorpos anti-cd40 para uso na prevenção de rejeição de enxerto |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11780927B2 (https=) |
| EP (1) | EP3774913A1 (https=) |
| JP (2) | JP6861301B2 (https=) |
| KR (1) | KR20200143718A (https=) |
| CN (1) | CN111971307A (https=) |
| AU (1) | AU2019252858A1 (https=) |
| BR (1) | BR112020020277A2 (https=) |
| CA (1) | CA3094600A1 (https=) |
| CL (1) | CL2020002622A1 (https=) |
| IL (1) | IL277828A (https=) |
| MX (1) | MX2020010722A (https=) |
| TW (1) | TW201943731A (https=) |
| WO (1) | WO2019198019A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020225736A1 (en) * | 2019-05-08 | 2020-11-12 | Novartis Ag | Anti-cd40 antibodies for use in treatment of t1dm and insulitis |
| CN116234909A (zh) * | 2020-08-21 | 2023-06-06 | 上海药明生物技术有限公司 | Cd40激动剂抗体和使用方法 |
| WO2022090194A1 (en) * | 2020-10-26 | 2022-05-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for assessing the area under the curve of an immunosuppressant and associated method and systems |
| EP4402174A1 (en) * | 2021-09-17 | 2024-07-24 | Novartis AG | Methods for prevention of graft rejection in xenotransplantation |
| WO2025117849A1 (en) * | 2023-11-28 | 2025-06-05 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025235683A1 (en) * | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| BRPI0417266B8 (pt) | 2003-12-25 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | anticorpo monoclonal, seu uso e composição farmacêutica |
| CN101014386A (zh) * | 2004-04-27 | 2007-08-08 | 诺华疫苗和诊断公司 | 拮抗性抗－cd40单克隆抗体及其使用方法 |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| BR112012024713B1 (pt) | 2010-03-31 | 2021-02-17 | Boehringer Ingelheim International Gmbh | anticorpo humanizado, seus usos e composição farmacêutica que o compreende |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US11780977B2 (en) * | 2020-08-10 | 2023-10-10 | Dover Chemical Corporation | Polymer compositions having an improved printable surface and related methods |
-
2019
- 2019-04-11 JP JP2019562323A patent/JP6861301B2/ja not_active Expired - Fee Related
- 2019-04-11 BR BR112020020277-0A patent/BR112020020277A2/pt not_active Application Discontinuation
- 2019-04-11 KR KR1020207032429A patent/KR20200143718A/ko not_active Withdrawn
- 2019-04-11 WO PCT/IB2019/052976 patent/WO2019198019A1/en not_active Ceased
- 2019-04-11 TW TW108112758A patent/TW201943731A/zh unknown
- 2019-04-11 MX MX2020010722A patent/MX2020010722A/es unknown
- 2019-04-11 EP EP19724250.6A patent/EP3774913A1/en not_active Withdrawn
- 2019-04-11 CA CA3094600A patent/CA3094600A1/en active Pending
- 2019-04-11 AU AU2019252858A patent/AU2019252858A1/en not_active Abandoned
- 2019-04-11 US US17/046,684 patent/US11780927B2/en active Active
- 2019-04-11 CN CN201980024663.8A patent/CN111971307A/zh active Pending
-
2020
- 2020-10-06 IL IL277828A patent/IL277828A/en unknown
- 2020-10-09 CL CL2020002622A patent/CL2020002622A1/es unknown
-
2021
- 2021-01-28 JP JP2021012521A patent/JP2021113190A/ja active Pending
-
2023
- 2023-09-01 US US18/459,922 patent/US20240287198A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020002622A1 (es) | 2021-04-16 |
| MX2020010722A (es) | 2020-11-06 |
| KR20200143718A (ko) | 2020-12-24 |
| JP2021113190A (ja) | 2021-08-05 |
| WO2019198019A1 (en) | 2019-10-17 |
| CA3094600A1 (en) | 2019-10-17 |
| JP2020519634A (ja) | 2020-07-02 |
| EP3774913A1 (en) | 2021-02-17 |
| US11780927B2 (en) | 2023-10-10 |
| US20240287198A1 (en) | 2024-08-29 |
| AU2019252858A1 (en) | 2020-10-08 |
| IL277828A (en) | 2020-11-30 |
| CN111971307A (zh) | 2020-11-20 |
| TW201943731A (zh) | 2019-11-16 |
| US20210079107A1 (en) | 2021-03-18 |
| JP6861301B2 (ja) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240287198A1 (en) | Anti-cd40 antibodies for use in prevention of graft rejection | |
| TWI774028B (zh) | 抗ａｌｋ２抗體及其用途 | |
| TWI875757B (zh) | T1dm和胰島炎治療中使用之抗cd40抗體 | |
| US20250206833A1 (en) | Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome | |
| CN107530419A (zh) | 治疗疾病的组合疗法 | |
| CN118924895A (zh) | 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案 | |
| KR20180039172A (ko) | 루푸스 신염의 치료를 위한 항-cd40 항체의 용도 | |
| KR20250099778A (ko) | 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질 | |
| CN111886252A (zh) | 促进胰岛细胞生长的方法 | |
| US20240366777A1 (en) | Anti-folate receptor conjugate combination therapy with bevacizumab | |
| TW202421661A (zh) | Igf1r抗體 | |
| RU2790558C2 (ru) | Антитела к cd40 для применения в лечении синдрома шегрена | |
| WO2025094976A1 (ja) | ヘモジデリンの沈着及び／又は滑膜肥厚の改善又は抑制剤 | |
| TW202402791A (zh) | 抗ｉｌ－２７抗體之用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |